IMR Press / CEOG / Volume 20 / Issue 3 / pii/1993026

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research

The effects of vanadate and epidermal gro\vth factor on the specific activities of phospholipase A2 and phosphatidylinositol -specific phospholipase C in human amnion cells

Show Less
1 Department of Obstetrics and Gynecology University of Tuebingen, (FRG)
2 The Cecil H. and Ida Green Center for Reproductive Biology Sciences, the University of Texas Southwestern Medical Center at Dallas, (USA)
Clin. Exp. Obstet. Gynecol. 1993, 20(3), 159–162;
Published: 10 September 1993
Abstract

We have evaluated the specific activity of phospholipase A2 (PLA2) and phosphatidylinositol-specific phospholipase C (PLC) in human amnion cells in monolayer culture that had not (CTL) or that had been treated with vanadate (VAN) and/or mouse epidermal growth factor (mEGF) for 4 h. It is known that both agents stimulate prostaglandin (PG) E2 synthesis in these cells. Phospholipase enzyme activities were determined in the 750 x g supernatant fraction of amnion cell homogenates under optimal in vitro conditions. The specific activity of PLA2 ranged from 1.1 to 1.25 nmol/mg protein/0.5 h and that of phosphatidylinositol-specific PLC from 1.04 to 1.2 mumol/mg protein/h. Treatment of amnion cell cultures with VAN and/or mEGF had no statistically significant effect on the specific activities of either phospholipases. Thus, we conclude that the stimulation of PGE2 production by VAN and mEGF is not due to an increase in the release of arachidonic acid from glycerophospholipid storage forms in human amnion cells.

Keywords
Vanadate
EGF
Phospholipases
Human amnion
Share
Back to top